nCino (NASDAQ:NCNO) reported robust financial results for its fiscal year 2026 on Tuesday, March 31, 2026, demonstrating continued momentum in the global digital transformation of banking.
Chagee Holdings (NASDAQ:CHA) announced its unaudited financial results for the fourth quarter and full year ended December 31, 2025, on Tuesday, March 31, 2026.
Phoenix Asia Holdings (NASDAQ:PHOE) reported unaudited financial results for the six-month period ended September 30, 2025, on Tuesday, revealing a challenging start to the fiscal year defined by compressed margins and lower top-line volume.
Bitfarms (NASDAQ:BITF) announced transformative full-year 2025 financial results and a major corporate restructuring on Tuesday, March 31, 2026, headlined by a shareholder-approved plan to redomicile to the United States and rebrand as Keel Infrastructure.
Novo Nordisk (NYSE:NVO) announced a strategic shift in its commercial approach on Tuesday, March 31, 2026, launching a multi-month subscription program for its flagship obesity medication, Wegovy.
McCormick & Company (NYSE:MKC) and Unilever announced a landmark agreement on Tuesday, March 31, 2026, to combine McCormick with Unilever’s global foods business.
Forum Markets (NASDAQ:FRMM), a fintech company focused on real-world asset tokenization, reported its fourth-quarter and full-year 2025 financial results and provided 2026 guidance on its scaling RWA platform.
Reading International (NASDAQ:RDI), a company engaged in cinema exhibition and real estate development, reported its fourth-quarter and full-year 2025 financial results.
OS Therapies (NYSE:OSTX) announced on Tuesday, March 31, 2026, that it has reached a pivotal regulatory milestone by submitting its Phase 2b clinical and biomarker data to the U.S. Food and Drug Administration (FDA) for a formal Pre-BLA (Biologics License Application) meeting.
NervGen Pharmaceutics (NASDAQ:NGEN) reported its full-year 2025 financial and operational results on Tuesday, March 31, 2026, marking a definitive shift toward pivotal-stage clinical development.
Cadrenal Therapeutics (NASDAQ:CVKD) reported its fourth-quarter and full-year 2025 financial results on Tuesday, March 31, 2026, marking a critical transition from mid-stage development to pivotal Phase 3 readiness for its lead candidate, CAD-1005.
Canton Strategic Holdings (NASDAQ:CNTN) reported its full-year 2025 financial results on Tuesday, March 31, 2026, marking its first complete fiscal year since pivoting to a dedicated digital asset and blockchain infrastructure strategy.
